Effects of kappa-opioid receptor ligands
on intracranial self-stimulation in rats
by
Todtenkopf MS, Marcus JF, Portoghese PS, Carlezon WA Jr.
Behavioral Genetics Laboratory,
Department of Psychiatry,
Harvard Medical School, McLean Hospital,
115 Mill Street, MRC 217,
MA 02478, Belmont, USA.
Psychopharmacology (Berl). 2004 Apr;172(4):463-70

ABSTRACT

RATIONALE. Elevations in cAMP response element binding protein (CREB) function within the mesolimbic system of rats reduce cocaine reward in place conditioning studies and increase immobility in the forced swim test. Each of these behavioral adaptations can be interpreted as a depressive-like effect (i.e., anhedonia, despair) that may reflect reduced activity of brain reward systems. Furthermore, each effect appears due to increases in CREB-mediated expression of dynorphin, since each is attenuated by intracranial injections of the kappa-opioid receptor antagonist norBNI. OBJECTIVES. Intracranial self-stimulation (ICSS) studies were conducted in rats to determine whether administration of a kappa-agonist would have depressive-like effects on brain stimulation reward, and whether pretreatment with a kappa-antagonist would attenuate any such effects. Conditions that have depressive effects in people (e.g., drug withdrawal) increase the threshold amounts of stimulation required to sustain ICSS in rats. METHODS. Sprague-Dawley rats with lateral hypothalamic stimulating electrodes were tested in a "curve-shift" variant of the ICSS procedure after systemic administration of the kappa-agonist U-69593 alone, the novel kappa-antagonist 5'-acetamidinoethylnaltrindole (ANTI) alone, or co-administration of both drugs. RESULTS. U-69593 dose dependently increased ICSS thresholds, suggesting that activation of kappa-receptors reduced the rewarding impact of the brain stimulation. ANTI had no effects on its own, but it attenuated increases in ICSS thresholds caused by the agonist. CONCLUSIONS. These data provide further evidence that stimulation of brain kappa-receptors may trigger certain depressive-like signs, and that kappa antagonists may have efficacy as antidepressants without having reward-related actions of their own.

Mu
Pain
Enadoline
Allodynia
Tolerance
Buprenorphine
Receptor subtypes
Nor-binaltorphimine
Fentanyl and ketamine
Kappa upregulation and addiction
kappa-Opioid withdrawal in Planaria
Kappa antagonists as future antidepressants?
Nalbuphine and anti-analgesia in men and women
Stress, dysphoria and the dynorphin kappa-opioid system
Indolomorphinan antagonists of the kappa-opioid receptor
The kappa receptor antagonist norbinaltorphimine as an antidepressant
JDTic: an antidepressant, anxiolytic kappa-selective opioid receptor antagonist

Refs
and further reading

HOME
HedWeb
Nootropics
cocaine.wiki
Future Opioids
BLTC Research
MDMA/Ecstasy
Superhapiness?
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family